Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR